alexa The Antioxidant Effects of Capparis Ovata and Deferasir
ISSN: 2155-9864

Journal of Blood Disorders & Transfusion
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

The Antioxidant Effects of Capparis Ovata and Deferasirox in Patients with Thalassemia Major

Handan Duman1, Duran Canatan1*, Güchan Alanoglu2, Recep Sutçu3 and Tufan Nayır4

1Department of Pediatric Hematology, Suleyman Demirel University, Turkey

2Department of Adult Hematology, Suleyman Demirel University, Turkey

3Department of Biochemistry, Suleyman Demirel University, Turkey

4Department of Public Health. Suleyman Demirel University, Turkey

*Corresponding Author:
Duran Canatan
Department of Pediatric Hematology
Suleyman Demirel University, Turkey
E-mail: [email protected]

Received date: June 07, 2013; Accepted date: June 27, 2013; Published date: June 30, 2013

Citation: Duman H, Canatan D, Alanoglu G, Sutçu R, Nayir T (2013) The Antioxidant Effects of Capparis Ovata and Deferasirox in Patients with Thalassemia Major. J Blood Disord Transfus 4:142.doi: 10.4172/2155-9864.1000142

Copyright: © Duman H, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



Iron overload and auto-oxidation of unpaired globin chains is the main cause of oxidative stress in thalassemia.
We aimed to show the additive antioxidant effect of capparis 􀁒􀁙􀁄􀁗􀁄 and deferasirox in thalassemic patients. A
total number of 40 thalassemia major patient aged between 7-30 years, who have been taken regular red cell
15 cc/kg/month to maintain Hb >10 gr/dl) and chelation (30 mg/kg/day ICL-670) for one year are involved. They
were divided into two groups as control and study group randomly. Both study and control groups were followed
by regular transfusion and chelation therapy. In addition study group has been taken capparis marmalade at the
breakfast with a dose of a dessert-spoon (12.5 gr) younger than 10 years and a soup-spoon (25 gr) older than 10
years for 6 months. Hematological and biochemical parameters, ferritin at every month and oxidative-antioxidant
status (MDA, CAT, Gpx, SOD) were measured at the beginning and at the end of the study. Serum ferritin and
MDA levels declined significiantly in both groups (for ferritin; control group p=0.00; study group p=0.00) during
the study but a much more decrease occured at MDA levels in the capparis given group (p=0.02). There was no
statistically significant difference between the groups at the initial and last SOD CAT, GPX, SOD levels. Further
more in the study group a significant decrease in liver function tests has been occured (AST p= 0.05, ALT p=
0.01). The high levels of MDA in iron overloaded thalassemic patients is the best marker of oxidative stres.
Generally decreased iron burden was associated with decreased oxidant damage. In vitro it was shown that
iron chelators such as deferoxamine and deferipron neutrolyse intraselluler free iron and inhibits oxidation. Our
findings suggest that combination of capparis with deferasirox maybe have additive effect on decreasing the
oxidative damage and hepatoxicity.

Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version